Tuesday, July 14, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
CAD-1005 Phase 2 Study Reported At Medical Meeting. Cadrenal presented data from its Phase 2 trial testing CAD-1005 in HIT (Heparin Induced Thrombocytopenia) at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress. As discussed in our Research Note on February 25, the trial did not meet its Primary Endpoint, but successfully characterized CAD-1005 and had unanticipated findings that were better than expected.
CAD-1005 Reduced Thrombotic Events Without Platelet Recovery. The Phase 2 placebo-controlled trial was designed to test CAD-1005 with standard anticoagulant therapy. Its Primary Endpoint was an improvement in platelet recovery, a biomarker for predicting thrombotic events and outcome. This primary endpoint did not meet statistical significance, although the secondary endpoint of reduction in thrombotic events showed a clinically meaningful improvement.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
